ABSTRACT

The FDA is proposing a new regulation, Patient Medication Information (PMI), to simplify medication and device information, enhancing patient understanding and adherence, promoting safety and safety in the medication guide industry. The PMI offers numerous benefits, including enhanced by treating various aspects of medication administration and patient knowledge, healthcare outcomes are improved and safety for patients is maintained. The FDA has proposed a rule to enhance patient clarity by requiring concise and easy-to-read information about a drug. The FDA discovered that existing Consumer Medication Information is not always clear to patients, despite the fact that patients often receive informational documents with their prescription medication. CDER developed a finalized PMI format for prescription drugs, focusing on key elements for patient safety and effectiveness, including medication component name, safety data, typical adverse effects, and directions for use. The FDA is investigating the use of "Patient Medication Information" (PMI), a new technique to ensure thesafe use of medical products, despite the complexity of labelling and warnings. This innovative approach seeks to improve health by giving patients easily understood, reliable, obtainable information and patient well-being and also FDA brought some of the limitations in the form of templates for better understanding the prescription and overall patient medication information template/ form as an example in the form of single sheet/one page document. Through this rule patients/consumers will take the medication without any confusion and also used in betterment of health. Keywords: FDA, CDER, Patient Medication, Prescription, Healthcare
Publication date: 01/12/2025

https://ijbpas.com/pdf/2025/December/MS_IJBPAS_2025_9691.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.12.9691